Calcipotriene, Betamethasone Dipropionate

Calcipotriene and Betamethasone Dipropionate Ointment is indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older. Calcipotriene and Betamethasone Dipropionate Ointment is a vitamin D analogue and corticosteroid combination product indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older. ( 1 )

12.1 Mechanism of Action Calcipotriene and Betamethasone Dipropionate Ointment combines the pharmacological effects of calcipotriene as a synthetic vitamin D 3 analogue and betamethasone dipropionate as a synthetic corticosteroid. However, while their pharmacologic and clinical effects are known, the exact mechanisms of their actions in plaque psoriasis are unknown.

Clinical clearance of Calcipotriene, Betamethasone Dipropionate (Vitamin D Analog) relies on local esterase/enzymatic cleavage of calcipotriene, betamethasone dipropionate with minimal hepatic cytochrome burden with a Surface-compartment clearance kinetics with low systemic half-life for Calcipotriene, Betamethasone Dipropionate half-life; patients absorbing at < 5% transdermal or mucosal systemic uptake from Calcipotriene, Betamethasone Dipropionate bioavailability typically observe target onset around initial local symptom modulation in 30–90 minutes; full tissue response over 1–3 weeks (calcipotriene, betamethasone dipropionate).

FDA clinical labeling for Calcipotriene, Betamethasone Dipropionate restricts administration in previous anaphylactoid or exfoliative reaction attributed to calcipotriene, betamethasone dipropionate; clinical scenarios where vitamin d analog exposure from calcipotriene, betamethasone dipropionate poses unacceptable risk across 50 ug/g / .643 mg/g Ointment, Therapeutic monitoring titration for Calcipotriene, Betamethasone Dipropionate (vitamin d analog), with self-reported patient tracking dominated by headache (7.6% of reports), nausea (7.4% of reports), fatigue (5.5% of reports).